KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesChange in TaxesChange in Working CapitalExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet Equity Issued and RepurchasedNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesSales of Property, Plant and Equipment
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Novartis Ag (NVS) Free Cash Flow (2016 - 2025)

Historic Free Cash Flow for Novartis Ag (NVS) over the last 17 years, with Q4 2025 value amounting to $2.9 billion.

  • Novartis Ag's Free Cash Flow fell 3952.85% to $2.9 billion in Q4 2025 from the same period last year, while for Dec 2025 it was $20.7 billion, marking a year-over-year increase of 899.13%. This contributed to the annual value of $20.7 billion for FY2025, which is 899.13% up from last year.
  • Latest data reveals that Novartis Ag reported Free Cash Flow of $2.9 billion as of Q4 2025, which was down 3952.85% from $6.9 billion recorded in Q3 2025.
  • Over the past 5 years, Novartis Ag's Free Cash Flow peaked at $7.0 billion during Q2 2025, and registered a low of $1.9 billion during Q1 2022.
  • In the last 5 years, Novartis Ag's Free Cash Flow had a median value of $4.4 billion in 2021 and averaged $4.3 billion.
  • Its Free Cash Flow has fluctuated over the past 5 years, first soared by 6088.72% in 2024, then tumbled by 3952.85% in 2025.
  • Over the past 5 years, Novartis Ag's Free Cash Flow (Quarter) stood at $4.3 billion in 2021, then grew by 1.68% to $4.4 billion in 2022, then tumbled by 33.14% to $3.0 billion in 2023, then skyrocketed by 60.89% to $4.8 billion in 2024, then tumbled by 39.53% to $2.9 billion in 2025.
  • Its Free Cash Flow stands at $2.9 billion for Q4 2025, versus $6.9 billion for Q3 2025 and $7.0 billion for Q2 2025.